Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K

Sassi, Mirja-Liisa; Eriksen, Heidi; Risteli, Leila; Niemi, Seija; Mansell, Jason P.; Gowen, Maxine; Risteli, Juha

doi:10.1016/s8756-3282(00)00235-0

Cited by 157 publications

(85 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Carboxy-terminal telopeptide of type-1 collagen is a surrogate marker for collagen degradation with a high specificity for cancer-induced bone resorption activity. 35 Furthermore, ICTP has been identified as a prognostic factor in MM patients, 15,16,18 which is now confirmed in this study in univariate and multivariate models in patients with newly diagnosed symptomatic MM. Notably ICTP, but not the presence or absence of lytic bone lesions, was a significant prognostic factor for survival.…”

Section: Discussionsupporting

confidence: 77%

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

et al. 2008

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 77%

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

et al. 2008

View full text Add to dashboard Cite

“…Two enzymatic pathways are involved in osteoclastic bone resorption, one involving cathepsin K and releasing NTx and type I collagen C-terminal telopeptide (CTx) from bone collagen, and the other involving matrix metalloproteinases and releasing ICTP but not NTx or CTx. [8][9][10] Thus, urinary NTx measures cathepsin K-mediated resorption and serum ICTP matrix metalloproteinases-mediated resorption of osteoclasts. The observed dissociation between the two markers could be due to a continuing increase in matrix metalloproteinase-mediated resorption together, even with reduced activity of cathepsin K.…”

Section: Discussionmentioning

confidence: 99%

Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation

Kananen

Volin

Tähtelä

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Osteoporotic fractures are potential long-term complications of bone marrow transplantation (BMT). We previously reported that bone mineral density (BMD) of patients undergoing allogeneic BMT decreased by 6% to 9% during the first 6 months after BMT and that bone turnover rate was still increased 1 year after BMT. BMT patients do not need lifelong immunosuppressive treatment, which should offer favorable circumstances for the recovery of BMD. Thus, 27 (14 women, 13 men) of 29 long-term survivors of our previous study were invited to a follow-up study at a median of 75 months after BMT. From 12 months after BMT the BMD of the lumbar spine had increased by 2.4% (P ‫؍‬ 0.002). The respective changes in femoral sites were ؉4.1% in the femoral neck (P ‫؍‬ 0.087), 4.0% in the trochanter (P ‫؍‬ 0.095), ؉4.7% in Ward's triangle (P ‫؍‬ 0.072) and ؉1.4% in the total hip (P ‫؍‬ 0.23). The markers of bone formation, serum osteocalcin and type I procollagen aminoterminal propeptide (PINP) had returned to control levels, but out of the markers of bone resorption the mean level of serum type I carboxyterminal telopeptide (ICTP) was 41% higher (P ‫؍‬ 0.0001) and that of urinary type I collagen N-terminal telopeptide/creatinine (NTx) 41% lower (P ‫؍‬ 0.0002) in patients than in con Keywords: bone marrow transplantation; osteoporosis; bone mineral density; bone markers; vitamin D Osteoporosis and osteoporotic fractures are potential longterm complications of not only solid organ transplants 1 but also of the bone marrow. 2,3 In our prospective study of 44 patients undergoing allogeneic bone marrow transplantation (BMT) bone mineral density (BMD) decreased by 6% in the lumbar spine and by 7% to 9% in the three femoral sites during the first 6 post-transplant months; no significant further decline occurred between 6 and 12 months. 2 Shortly after BMT bone loss was explained by uncoupling between increased bone resorption and decreased bone formation. 2 At the end of 1-year follow-up both resorption and formation markers were elevated, indicating accelerated bone turnover in survivors. 2 Unlike transplant recipients of solid organs, recipients of hemopoietic transplants do not need lifelong immunosuppression, and glucocorticoids and cyclosporine A can usually be stopped. This fact, together with a relatively young age of BMT recipients offer the bone favourable circumstances to recover, the magnitude of which has not been addressed in previous studies. Thus, we invited the long-term survivors of our original patient population to a follow-up study, in which their BMD and bone turnover state were re-evaluated at a median of 6 years after BMT. The values were compared to those obtained at the end of the previous 1-year follow-up, and biochemical data were compared to those produced by sex-matched controls. The vitamin D status of the patients was also evaluated. Patients and methods PatientsTwenty-nine of 44 patients who had received an allogeneic bone marrow transplant and taken part in our previous study were still alive and...

show abstract

“…27 This antigen is liberated when type I collagen is degraded by matrix metalloproteinases. 22,28 In contrast to the approach used in the ICTP assay, the CTX-I (b-CTX) antigen is liberated when type I collagen is degraded by cathepsin K, but not by matrix metalloproteinases. 26 The recognized antigen must be cross-linked, but can be imbedded into fragments of the C-terminal telopeptide of variable size (1000-10 000 Da).…”

Section: Biochemistry Of Bone Markersmentioning

confidence: 99%

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

et al. 2010

View full text Add to dashboard Cite

Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during antimyeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino-and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.

show abstract

Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K

Cited by 157 publications

References 26 publications

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

Contact Info

Product

Resources

About